Cantor Fitzgerald Comments on RNAC FY2026 Earnings

Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Cartesian Therapeutics in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska forecasts that the company will post earnings of ($3.84) per share for the year. The consensus estimate for Cartesian Therapeutics' current full-year earnings is $4.56 per share.

A number of other research analysts have also weighed in on RNAC. HC Wainwright reissued a "buy" rating and issued a $40.00 target price on shares of Cartesian Therapeutics in a research note on Wednesday, April 9th. Needham & Company LLC reduced their price objective on Cartesian Therapeutics from $41.00 to $40.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $43.00.

Cartesian Therapeutics Trading Down 1.6%

NASDAQ:RNAC traded down $0.17 during trading hours on Tuesday, hitting $10.24. 41,587 shares of the stock were exchanged, compared to its average volume of 88,152. The firm's fifty day moving average price is $10.58 and its 200 day moving average price is $15.58. Cartesian Therapeutics has a 52-week low of $8.46 and a 52-week high of $30.66. The company has a market cap of $265.77 million, a P/E ratio of -0.19 and a beta of 0.33.

Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.07). The company had revenue of $1.10 million during the quarter, compared to analysts' expectations of $0.69 million.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of RNAC. Virtus ETF Advisers LLC purchased a new position in Cartesian Therapeutics in the 4th quarter valued at approximately $63,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Cartesian Therapeutics by 22.8% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,562 shares of the company's stock worth $82,000 after buying an additional 847 shares during the last quarter. Wells Fargo & Company MN raised its stake in shares of Cartesian Therapeutics by 112.7% during the 4th quarter. Wells Fargo & Company MN now owns 4,847 shares of the company's stock worth $87,000 after buying an additional 2,568 shares during the last quarter. Corebridge Financial Inc. boosted its position in shares of Cartesian Therapeutics by 32.6% in the 4th quarter. Corebridge Financial Inc. now owns 5,122 shares of the company's stock worth $92,000 after buying an additional 1,258 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Cartesian Therapeutics by 44.8% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,786 shares of the company's stock valued at $104,000 after acquiring an additional 1,789 shares during the last quarter. Hedge funds and other institutional investors own 86.95% of the company's stock.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.